


The aim of the fund is to achieve long term growth from investments principally in European equities, excluding the UK.
| Name | % Net Assets | 
|---|---|
| Roche | 4.0% | 
| Novartis | 3.7% | 
| BNP Paribas | 3.1% | 
| Novo-Nordisk | 3.0% | 
| Telefónica | 2.6% | 
| Allianz SE | 2.6% | 
| Nordea Bank | 2.5% | 
| SAP | 2.4% | 
| Ericsson | 2.4% | 
| Banco Bilbao Vizcaya Argentaria | 2.3% | 
| Key | % Net Assets | 
|---|---|
| 4.0% | |
| 3.7% | |
| 3.1% | |
| 3.0% | |
| 86.2% | 
| Date | 23-Apr-2020 | 
|---|---|
| NAV | 91.26p | 
| Currency | GBP | 
| Change | -0.48p | 
| % | -0.52% | 
| YTD change | 91.26p | 
| YTD % | n/a | 
| Fund Inception | 28/10/2011 | 
|---|---|
| Fund Manager | Mark Page / Laurent Millet | 
| TER | 2.25 (30-Apr-2012) | 
| Minimum Investment | |
|---|---|
| Initial | £1000 | 
| Additional | n/a | 
| Savings | £50 | 
| Charges | |
|---|---|
| Initial | 5.25% | 
| Annual Mang't | 1.50% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| No risk data available. | |
You are here: research